JACOBIO-B (1167.HK)
- Previous Close
3.640 - Open
3.600 - Bid 3.950 x --
- Ask 3.960 x --
- Day's Range
3.600 - 4.000 - 52 Week Range
1.200 - 4.300 - Volume
6,944,403 - Avg. Volume
8,331,700 - Market Cap (intraday)
3.123B - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-0.230 - Earnings Date Mar 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.05
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under multiple stage studies for indications such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications including NSCLC, PDAC, CRC, and other solid tumors; JAV-8263, a BET inhibitor for solid and liquid tumors; JAB-2485 Aurora A inhibitor, JAB-30355 P53 Y220C inhibitor, JAB-BX102 CD73 mAb inhibitor, JAB-26766 PARP 7 inhibitor, and JAB-BX300 LIF inhibitor under trials for solid tumor indications; and JAB-24114, a glutamine-utilizing enzyme for solid tumor and hematological malignancy indications. The company also develops IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications. It has a collaboration agreement with Merck for cetuximab for combination trials. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.
www.jacobiopharma.comRecent News: 1167.HK
View MorePerformance Overview: 1167.HK
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1167.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1167.HK
View MoreValuation Measures
Market Cap
3.12B
Enterprise Value
2.03B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.35
Price/Book (mrq)
3.15
Enterprise Value/Revenue
12.11
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-100.00%
Return on Assets (ttm)
-9.01%
Return on Equity (ttm)
-15.60%
Revenue (ttm)
155.71M
Net Income Avi to Common (ttm)
-155.71M
Diluted EPS (ttm)
-0.230
Balance Sheet and Cash Flow
Total Cash (mrq)
1.17B
Total Debt/Equity (mrq)
16.47%
Levered Free Cash Flow (ttm)
-41.72M